Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/57598
Title: Evaluation of pediatric rheumatologists' approach to rituximab use: a questionnaire study
Authors: Sunar Yayla, Emine Nur
Gezgin Yıldırım, Deniz
Adıgüzel Dündar, Hatice
Adrovic, Amra
Akboru, Elifsu Gözde
Aktay Ayaz, Nuray
Aliyev, Emil
Avar Aydın, Pınar Özge
Aydın, Fatma
Baba, Özge
Bağlan, Esra
Bora Makay, Balahan
Bozkaya Yücel, Burcu
Çakan, Mustafa
Çelikel, Elif
Demir, Ferhat
Demir, Selcan
Demirkan, Fatma Gül
Ekici Tekin, Zahide
Esmeray Şenol, Pelin
Guliyeva, Vefa
Güngörer, Vildan
İşgüder, Rana
Kalyoncu, Mukaddes
Karadağ, Şerife Gül
Kısaoğlu, Hakan
Kışla Ekinci, Rabia Miray
Kızıldağ, Zehra
Kurt, Tuba
Özdel, Semanur
Özdemir Çiçek, Sümeyra
Öztürk, Kübra
Polat, Merve Cansu
Sezer, Müge
Sönmez, Hafize Emine
Sözeri, Betül
Şener, Seher
Taşkın, Sema Nur
Türkuçar, Serkan
Ünsal, Erbil
Yıldız, Çisem
Bakkaloğlu, Sevcan A.
Keywords: Rituximab
Survey
Adverse events
Vaccination
Pediatric rheumatology
Rheumatoid-Arthritis
Therapy
Safety
Management
Publisher: Springer
Abstract: Rituximab (RTX) is a chimeric monoclonal antibody that targets the CD20 antigen on B cells and is used in various autoimmune disorders. In this study, we aimed to measure the awareness of pediatric rheumatologists about the use of RTX through a survey. Between February and March 2023, a 42-question survey was sent via email to pediatric rheumatology specialists in Turkey. The participants were questioned for which diagnoses and system involvement they preferred to use RTX, which routine tests they performed, vaccination policy, and adverse events that occurred during or after infusion. Forty-one pediatric rheumatologists answered the survey. They prescribed RTX most frequently for systemic lupus erythematosus (87.8%) and ANCA-associated vasculitis (9.8%). Prior to the administration of RTX, 95% of clinicians checked renal and liver function tests, as well as immunoglobulin levels. The most frequently tested hepatitis markers before treatment were HBsAg and anti-HBs antibody (97.6%), while 85.4% of rheumatologists checked for anti-HCV. Clinicians (31.4%) reported that they postpone RTX infusion 2 weeks following an inactivated vaccine. Sixty-one percent of rheumatologists reported starting RTX treatment 1 month after live vaccines, while 26.8% waited 6 months. The most frequent adverse events were an allergic reaction during RTX infusion (65.9%), hypogammaglobulinemia (46.3%), and rash (36.6%). In the event of hypogammaglobulinemia after RTX treatment, physicians reported that they frequently (58.5%) continued RTX after intravenous immunoglobulin administration.Conclusions: RTX has become a common treatment option in pediatric rheumatology in recent years. Treatment management may vary between clinician such as vaccination and routine tests. What is Known:center dot During the course of rituximab therapy, clinicians should be attentive to specific considerations in pre-treatment, during administration, and in post-treatment patient monitoring.What is New:center dot There are differences in practice among clinicians in the management of RTX therapy. These practice disparities have the potential to impact the optimal course of treatment.center dot This study highlights that standardized guidelines are needed for RTX treatment in pediatric rheumatology, particularly for vaccination policies and routine tests.
URI: https://doi.org/10.1007/s00431-024-05654-9
https://hdl.handle.net/11499/57598
ISSN: 0340-6199
1432-1076
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Show full item record



CORE Recommender

Page view(s)

24
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.